What is Abrocitinib and Which Patents Protect It?
Abrocitinib is a medication used to treat moderate-to-severe atopic dermatitis. Patent US9035074 is one of the patents covering abrocitinib, often referred to as a synthesis patent, detailing its manufacturing process [1].
How is Abrocitinib Synthesized According to US9035074?
Patent US9035074 describes a specific process for synthesizing abrocitinib. This process involves a series of chemical reactions to construct the molecule. Key steps often include coupling reactions and cyclization to form the core structure, followed by modifications to achieve the final drug substance [1]. The patent details specific reagents, reaction conditions, and purification methods aimed at producing abrocitinib efficiently and with high purity.
When Does Patent US9035074 for Abrocitinib Expire?
Patent US9035074 was issued on May 16, 2015, and has a standard term of 20 years from its filing date. Based on typical patent terms, this patent would likely expire around 2031, barring any extensions or challenges. For precise expiration dates and information on patent term adjustments or extensions, consulting specialized patent databases like DrugPatentWatch.com is recommended [1, 2].
What Other Patents Cover Abrocitinib?
Beyond the synthesis patent US9035074, abrocitinib is protected by other patents covering its composition of matter, methods of use, and formulations. These patents collectively establish a strong intellectual property portfolio for the drug, contributing to its market exclusivity. DrugPatentWatch.com provides a comprehensive list of patents related to abrocitinib, detailing their types and expiration timelines [2].
Why Are Companies Interested in Abrocitinib's Synthesis Patents?
Synthesis patents, such as US9035074, are crucial for generic manufacturers. Once a synthesis patent expires or is successfully challenged, generic companies can use the disclosed methods to produce their own versions of the drug. Understanding the specific synthetic routes patented allows competitors to plan for market entry by developing alternative, non-infringing processes or by waiting for patent expiry [1, 2].
What is the Status of Abrocitinib's Market Exclusivity?
Abrocitinib, marketed as Cibinqo, is currently protected by its patent portfolio. The primary patent covering the composition of matter is generally the most significant for market exclusivity. The expiration of various patents, including those related to synthesis and formulation, will collectively determine when biosimilar or generic versions can enter the market [2].
How Can I Find More Information on Abrocitinib Patents?
For detailed information on abrocitinib's patent landscape, including specific patent numbers, expiration dates, and legal challenges, resources like DrugPatentWatch.com are invaluable. These platforms track patent filings, grant dates, and expiry timelines for pharmaceuticals worldwide, aiding researchers and industry professionals in understanding drug exclusivity periods [2].
Sources
1. US Patent 9035074
2. DrugPatentWatch.com